 - Low- and intermediate-risk MDS that has failed to achieve any hematologic improvement after at least 4 cycles of induction therapy or has relapsed after any duration of any hematologic response. Prior therapy with azanucleosides i.e., azacitidine, decitabine, biologic therapies i.e., lenalidomide, rigosertib and hematopoietic cell transplant are permissible; 